The top 100 stock
market authors
selected for publication
market authors
selected for publication
Vanda Pharmaceuticals, Inc. (VNDA) ()
|
|
|
| 52wk high: | |
| 52wk low: | |
| EPS: | |
| PE: | |
| Dividend: | |
| Yield: | |
| Market Cap: | |
| Exchange: |
Articles on Vanda Pharmaceuticals, Inc. (VNDA) by latest | most commented
- Vanda Pharmaceuticals: Heavily Undervalued
- Vanda Pharmaceuticals Comes Back from the Dead
- Big Lineup of Healthcare Stocks Crack the Russell 3000 Index
- SAC Capital Discloses Vanda Pharmaceuticals Stake
- Competitive Technologies, Aethlon Medical: Pain Relief Without the Pills
- Titan Pharmaceuticals' Story Is Just Beginning
- Vanda Pharmaceuticals: A Biotech Stock Worth Watching
- Vanda Holding Up Well
- Four Small Caps to Watch: VNDA, COT, DTG, LNET
- Cell Therapeutics Sells $20M in Common Stock, Warrants
- Monday's Options Recap
- Small-Cap Biotechs: How to Separate the Contenders from the Pretenders
- Vanda Snaps Up Victory from the Jaws of Defeat
- Thursday's Options Recap
- Vanda Pharma Surges on FDA Approval
- Vanda Pharmaceuticals: Tomorrow's Headline Stock
- Vanda Pharma: An Extreme FDA Trade That Paid; 9 More to Go
- Tang Capital Partners' Proxy Statement for Vanda Pharmaceuticals Calls for Liquidation
- 12 Extreme FDA Trades on New Product Decisions
- The Ten Most Promising Net Cash Stocks
- Trading FDA Decisions: 14 Candidates
- 73 Decision Dates on Updated FDA Calendar
- Vanda's Schizophrenia Drug Goes Down for the Last Time
- Monday Options Update: MER, AMGN, SLW, VNDA, PFG, HW
- Thursday's Options Report: MSFT, VNDA, NVTL, XLF, RIMM, GM, ZLC
- 3 Positives From Vanda's Conference Call
- NeurogesX, Vanda Would Do Well To Find Themselves A Partner
- Vanda Pharmaceuticals: Finding Reassurance In Institutional Investors and Fair Value Calculations
- Vanda Pharmaceuticals' Pipeline Nearing FDA Stage
- Vanda Pharmaceuticals Should Jump On Bullish Note
- Potential Acquisitions May Prove Positive For Vanda Pharmaceuticals
- SAC Capital's 2007 Transactions: This Hedge Fund Has Been Busy
- Biotech Stocks: Abbott Sells Lab Division to GE for $8 Billion
- Biotech Rises To New Record High
- Eye on Vanda Pharmaceuticals
- Top Picks for 2007 from JPMorgan HealthCare Analysts
- 2007: The Year Of Biotech IPOs?
- Vanda Schizophrenia Drug Meets Phase III Endpoint
- Vanda's Success Pays For MedImmune Investors
- Vanda Pharmaceuticals' Insomnia Drug Registers Positive Results
- Amicus IPO: A Very Risky Prospect (AMTX)
-
The Seeking Alpha 100
See all
Seeking Alpha 100 » -
Fastest Climbers
Authors with the largest
increase in followers
in the last 7 days-
1
David Fry
-
2
Philip Davis
-
3
Bill Gross
-
4
Tyler Durden
-
5
TraderMark
Fastest Climbers » -
1
-
Top Commenters
Top commenters,See all
as ranked by their peers
Top Commenters » -
Top Instabloggers
The 100 most activeSee all
Instabloggers.
Top Instabloggers » -
Top StockTalkers
TopSee all
StockTalkers.
Top StockTalkers »
